Browse CD59

Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Note=Soluble form found in a number of tissues.
Domain PF00021 u-PAR/Ly-6 domain
Function

Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.; FUNCTION: The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.

> Gene Ontology
 
Biological Process GO:0001905 activation of membrane attack complex
GO:0001969 regulation of activation of membrane attack complex
GO:0001971 negative regulation of activation of membrane attack complex
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002920 regulation of humoral immune response
GO:0002921 negative regulation of humoral immune response
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006900 membrane budding
GO:0006901 vesicle coating
GO:0006903 vesicle targeting
GO:0006956 complement activation
GO:0006959 humoral immune response
GO:0007159 leukocyte cell-cell adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010955 negative regulation of protein processing
GO:0016050 vesicle organization
GO:0016485 protein processing
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030449 regulation of complement activation
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0045785 positive regulation of cell adhesion
GO:0045861 negative regulation of proteolysis
GO:0045916 negative regulation of complement activation
GO:0046651 lymphocyte proliferation
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048207 vesicle targeting, rough ER to cis-Golgi
GO:0048208 COPII vesicle coating
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050817 coagulation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050878 regulation of body fluid levels
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051604 protein maturation
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070613 regulation of protein processing
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0072376 protein activation cascade
GO:0090114 COPII-coated vesicle budding
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903317 regulation of protein maturation
GO:1903318 negative regulation of protein maturation
GO:2000257 regulation of protein activation cascade
GO:2000258 negative regulation of protein activation cascade
Molecular Function GO:0001848 complement binding
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0012507 ER to Golgi transport vesicle membrane
GO:0030055 cell-substrate junction
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0031225 anchored component of membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0031362 anchored component of external side of plasma membrane
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0042383 sarcolemma
GO:0043209 myelin sheath
GO:0043218 compact myelin
GO:0046658 anchored component of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-166658: Complement cascade
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-977606: Regulation of Complement cascade
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD59 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD59 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22531721Endometrial Serous AdenocarcinomaInhibit immunityDownregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
19380765Colorectal carcinomaInhibit immunity (T cell function)In this study, we explored the role of CD59 on human CD4(+) T cells. Our data demonstrate that CD59 is up-regulated on activated CD4(+) T cells and serves to down-modulate their activity in response to polyclonal and Ag-specific stimulation. The findings were striking and indicated that blockade of CD59 significantly enhanced the CD4(+) T cell response to two different tumor Ags. These data highlight the potential for manipulating CD59 expression on T cells for boosting weak immune responses, such as those found in individuals with cancer.
23474221Breast Carcinoma; Lung Carcinoma; Ovarian CarcinomaInhibit immunity (T cell function); essential for immunotherapyThe therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement-mediated attack, primarily through the over-expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Delivery of chemically stabilized anti-mCRP siRNAs using cationic lipoplexes, AtuPLEXes, to HER2-over-expressing BT474, SK-BR-3 (breast), SKOV3 (ovarian) and Calu-3 (lung) cancer cells reduced mCRPs expression by 85-95%.
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD59 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD59 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4450.198
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9580.771
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0790.973
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0930.798
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3850.838
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6970.77
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3280.599
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3260.904
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3930.899
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1060.969
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6860.868
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3090.00181
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD59 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD59. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD59. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD59.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD59. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD59 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD59 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD59
NameCD59 molecule, complement regulatory protein
Aliases 16.3A5; EJ16; EJ30; EL32; G344; p18-20; MIC11; MIN1; MSK21; MIN2; MIN3; CD59 antigen p18-20 (antigen identif ......
Chromosomal Location11p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD59 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.